Related Experiment Video
Updated: May 13, 2026
07:02
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
Drug discovery for spinal muscular atrophy
Brunhilde Wirth Phd1, Markus Riessland Msc, Eric Hahnen Mba
1Institute of Human Genetics, University of Cologne, Kerpener Street 34, 50931 Cologne, Germany. brunhilde.wirth@uk-koeln.de.
Expert Opinion on Drug Discovery
|March 15, 2013
Summary
Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disorder. Emerging therapies aim to increase functional survival motor neuron protein (SMN) by targeting the SMN2 gene, potentially offering a cure.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Background:
- Spinal muscular atrophy (SMA) is a fatal autosomal recessive neuromuscular disorder.
- Patients with SMA lack functional survival motor neuron 1 (SMN1) protein.
- Disease severity correlates with the number of SMN2 gene copies.
Purpose of the Study:
- To review current therapeutic strategies for SMA.
- To evaluate drugs targeting SMN2 gene transcription, splicing, or protein stabilization.
- To discuss the potential of gene-targeted therapies for SMA.
Main Methods:
- Literature review of identified drugs for SMA.
- Analysis of drug mechanisms: transcription activation, splicing correction, protein stabilization.
- Assessment of drug efficacy in increasing SMN protein levels.
Main Results:
- Several drugs have been identified that modulate SMN2 gene expression and protein levels.
- Some drugs demonstrate beneficial effects in increasing SMN protein in SMA patients.
- Placebo-controlled clinical trial data are still pending.
Conclusions:
- SMA treatment is advancing with drugs targeting the SMN2 gene.
- Gene-specific therapies hold promise for curing or ameliorating SMA.
- SMA may become a model for treating inherited disorders through gene modulation.
